modelAmrubicin

Diagram of Amrubicin

Extends from Pharmacolibrary.Drugs.ATC.L.L01DB10.

Information

name:Amrubicin
ATC code:L01DB10
route:intravenous
compartments:2
dosage:40mg
volume of distribution:54.0L
clearance:40.9L/h/m2
other parameters in model implementation

Amrubicin is a synthetic anthracycline antitumor agent used in the treatment of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). It acts primarily as a topoisomerase II inhibitor. Amrubicin is approved for use in some countries, such as Japan, primarily for lung cancer treatment.

Pharmacokinetics

Pharmacokinetic parameters were assessed in adult Japanese patients with advanced non-small cell lung cancer and small cell lung cancer following intravenous administration.

References

    Parameters

    TypeNameDefaultDescription
    Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
    Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
    Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
    Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
    Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
    Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
    Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
    Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
    IntegeradminCount (from PK_1C)8number of dose administered (1)
    Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
    Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
    Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
    Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
    Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
    Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
    Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

    Connectors

    TypeNameDefaultDescription
    Types.ConcentrationOutputC_central (from PK_1C)
    Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
    Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
    Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

    Components

    TypeNameDefaultDescription
    Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
    Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
    Sources.PeriodicDoseperiodicDose (from PK_1C)
    Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
    Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
    Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

    Revisions

    • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)